---
figid: PMC8591697__43556_2021_38_Fig2_HTML
figtitle: Targeting regulatory T cells for immunotherapy in melanoma
organisms:
- Homo sapiens
- Mus musculus
- Adenoviridae
organisms_ner:
- Homo sapiens
- Mus musculus
- Drosophila melanogaster
pmcid: PMC8591697
filename: 43556_2021_38_Fig2_HTML.jpg
figlink: /pmc/articles/PMC8591697/figure/Fig2/
number: F2
caption: Immune suppressive functions of Tregs in the TME. Tumor cells can produce
  soluble factors (IL-10 and TGF-β), exosomes, and biological-competent proteins (Galectin
  9 and PD-L1), which activate Tregs in the TME. Tregs release anti-inflammatory cytokines
  (IL-10, IL-35, and TGF-β) that directly inhibit the proliferation of effector T
  cells and neutrophils. They also produce perforin and granzymes to damage cell membrane
  and induce T cell apoptosis. In addition, high expression of CD39 and CD73 on Tregs
  facilitates the conversion of extracellular ATP to adenosine reducing the expansion
  of effector T cells. Moreover, Tregs consume IL-2 by expressing high level of CD25
  (IL-2 receptor) and inhibit the proliferation of effector T cells. Tregs have been
  suggested to directly inhibit B cell, M2 macrophage, and effector T cells via the
  PD-1/PD-L1 pathway. Furthermore, Tregs contact with DCs through CTLA-4 and LAG-3.
  Blocking CTLA-4 can decrease the CD86/80 expression leading to upregulation of IDO.
  Tregs decrease the proliferation and effector functions of NK cells through IL-2
  starvation and TGF-β dependent manner
papertitle: Targeting regulatory T cells for immunotherapy in melanoma.
reftext: Lili Huang, et al. Mol Biomed. 2021 Dec;2:11.
year: '2021'
doi: 10.1186/s43556-021-00038-z
journal_title: Molecular Biomedicine
journal_nlm_ta: Mol Biomed
publisher_name: Springer Singapore
keywords: Tregs | Melanoma | Immunotherapy | Immune suppression
automl_pathway: 0.9062238
figid_alias: PMC8591697__F2
figtype: Figure
redirect_from: /figures/PMC8591697__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8591697__43556_2021_38_Fig2_HTML.html
  '@type': Dataset
  description: Immune suppressive functions of Tregs in the TME. Tumor cells can produce
    soluble factors (IL-10 and TGF-β), exosomes, and biological-competent proteins
    (Galectin 9 and PD-L1), which activate Tregs in the TME. Tregs release anti-inflammatory
    cytokines (IL-10, IL-35, and TGF-β) that directly inhibit the proliferation of
    effector T cells and neutrophils. They also produce perforin and granzymes to
    damage cell membrane and induce T cell apoptosis. In addition, high expression
    of CD39 and CD73 on Tregs facilitates the conversion of extracellular ATP to adenosine
    reducing the expansion of effector T cells. Moreover, Tregs consume IL-2 by expressing
    high level of CD25 (IL-2 receptor) and inhibit the proliferation of effector T
    cells. Tregs have been suggested to directly inhibit B cell, M2 macrophage, and
    effector T cells via the PD-1/PD-L1 pathway. Furthermore, Tregs contact with DCs
    through CTLA-4 and LAG-3. Blocking CTLA-4 can decrease the CD86/80 expression
    leading to upregulation of IDO. Tregs decrease the proliferation and effector
    functions of NK cells through IL-2 starvation and TGF-β dependent manner
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - APRT
  - MFAP1
  - ATP8A2
  - TGFB1
  - TGFB2
  - TGFB3
  - CD86
  - CD80
  - ICOSLG
  - ENTPD1
  - NT5E
  - IL10
  - APP
  - AAAS
  - AAA1
  - TNFSF4
  - LAG3
  - TNFRSF4
  - CD274
  - PDCD1LG2
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - HAVCR2
  - IL2RA
  - ISG20
  - IL2
  - CD163
  - MRC1
  - Tgfb1
  - Ltbp1
  - Cd86
  - Cd80
  - Icosl
  - Entpd1
  - Nt5e
  - Il10
  - Aaas
  - H2
  - Tnfsf4
  - Lag3
  - Tnfrsf4
  - Cd274
  - Pdcd1lg2
  - Pdcd1
  - Havcr2
  - Lgals9
  - Il2ra
  - Il2
  - Cd163
  - Mrc1
  - Amph
  - ATPsynbeta
  - Atpalpha
  - dpp
  - gbb
  - put
  - mav
  - tRNA:Lys-TTT-1-1
  - tRNA:Lys-TTT-2-4
  - tRNA:Lys-TTT-2-1
  - tRNA:Lys-TTT-2-2
  - tRNA:Lys-TTT-2-5
  - tRNA:Lys-TTT-2-3
  - Myo61F
  - pana
  - galectin
---
